Researchers developed a long-acting protein-based therapeutic by fusing human erythropoietin to engineered albumin, showing a 5.7-day plasma half-life and improved mucosal barrier crossing. The fusion protein maintained therapeutic function and increased red blood cell production.
Researchers uncover the placenta distinguishes between antibodies and albumin, allowing for the design of long-acting biologic medicines with reduced fetal exposure. Fusion of IgG antibodies to albumin inhibits transport across the placenta, enabling the development of safer treatments during pregnancy.
A new study reveals that increasing NAD⁺ levels corrects RNA splicing mistakes, improving brain function and restoring memory in animal models of Alzheimer's disease. The researchers discovered a previously unidentified pathway involving the protein EVA1C, which plays a crucial role in correcting tau-related neuronal damage.
Researchers designed long-acting human albumin-fused FIX variants with unique pharmacokinetic properties, including extended plasma half-lives and enhanced extravascular distribution. The findings endorse the use of engineered albumin-fused FIX variants as personalized therapy options for hemophilia B.
Researchers highlight NAD+ supplements as potential key to healthier ageing and disease prevention, but call for larger studies. Early trials report improvements in memory, movement, and metabolism.